Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12674143 | 0.88 | NCF1 (0.41) | SAT1DRD3CHRM3CYP2D6MAOB | |
| SCHEMBL12778310 | 0.88 | NCF1 (0.41) | SAT1DRD3CHRM3CYP2D6MAOB | |
| SCHEMBL9036781 | 0.84 | ADH1B (0.41) | SMN1; SMN2KCNH2CHRM2ADRA2ACHRM1 | |
| SCHEMBL27323800 | 0.81 | CCR2 (0.38) | SAT1KCNH2CYP2D6CCR2BCHE | |
| SCHEMBL19781756 | 0.81 | — | — | |
| SCHEMBL4874323 | 0.79 | SMN1; SMN2 (0.37) | SMN1; SMN2KCNH2CHRM2ADRA2ACHRM1 | |
| SCHEMBL19575592 | 0.79 | CHRM2 (0.38) | SMN1; SMN2KCNH2CHRM2ADRA2ACHRM1 | |
| SCHEMBL2885366 | 0.79 | CHRM2 (0.38) | SMN1; SMN2KCNH2CHRM2ADRA2ACHRM1 | |
| SCHEMBL24535944 | 0.78 | KCNH2 (0.38) | SAT1KCNH2DRD3CYP2D6DPP4 | |
| SCHEMBL24510986 | 0.77 | ADH1B (0.57) | SMN1; SMN2KCNH2CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020016315-A1 | FUSED DIHYDROINDAZOLE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-01-23 | — | — | WO | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
| US-9790229-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9249146-B2 | Bruton'S tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-10-16 | — | — | US | disclosed |
| US-8785440-B2 | Bruton's tyrosine kinase inhibitors | BIOGEN IDEC MA, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | SAT1 4545/4885SMN1; SMN2 4292/4885KCNH2 3336/4885 |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | SAT1 4545/4885SMN1; SMN2 4292/4885KCNH2 3336/4885 |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | SAT1 4545/4885SMN1; SMN2 4292/4885KCNH2 3336/4885 |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | SAT1 4545/4885SMN1; SMN2 4292/4885KCNH2 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.